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Huntington’s disease (HD) is an inherited neuro-
degenerative disease caused by a glutamine
repeat expansion in huntingtin protein. Tran-
scriptional deregulation and altered energy me-
tabolismhavebeen implicated inHDpathogene-
sis.We report here thatmutanthuntingtin causes
disruption ofmitochondrial function by inhibiting
expression of PGC-1a, a transcriptional co-
activator that regulates several metabolic pro-
cesses, including mitochondrial biogenesis and
respiration. Mutant huntingtin represses PGC-
1a gene transcription by associating with the
promoter and interfering with the CREB/TAF4-
dependent transcriptional pathway critical for
the regulation of PGC-1a gene expression.
Crossbreeding of PGC-1a knockout (KO) mice
withHDknockin (KI)mice leads to increasedneu-
rodegeneration of striatal neurons and motor
abnormalities in the HD mice. Importantly, ex-
pression of PGC-1a partially reverses the toxic
effects of mutant huntingtin in cultured striatal
neurons. Moreover, lentiviral-mediated delivery
of PGC-1a in the striatum provides neuroprotec-
tion in the transgenic HD mice. These studies
suggest a key role for PGC-1a in the control of
energy metabolism in the early stages of HD
pathogenesis.
INTRODUCTION
Huntington’s disease (HD) is a progressive and fatal neu-
rological disorder that is characterized phenotypically by
involuntary movements and psychiatric disturbances
(Vonsattel and DiFiglia, 1998). The gene huntingtin, which
is mutated in HD patients, contains an expanded polyglu-
tamine repeat within exon 1. The number of polyglutaminediseases continues to grow, and they share several com-
mon features, including neurodegeneration, a dominant
pattern of inheritance and genetic anticipation (Zoghbi
and Orr, 2000). In HD, mutant huntingtin is expressed
ubiquitously, but selective cell loss is observed in the
brain, particularly in the caudate and putamen of the
striatum (Vonsattel and DiFiglia, 1998).
Many proteins containing polyglutamine-rich regions
function as transcription factors (Alba and Guigo, 2004).
Interactions of mutant huntingtin with several transcription
factors have been demonstrated, suggesting that mutant
huntingtin may be directly involved in the regulation of
gene transcription (Sugars and Rubinsztein, 2003). For ex-
ample, mutant huntingtin was shown to repress transcrip-
tion by interfering with activator/coactivator interactions
(Sp1/TAF4) in brain samples from presymptomatic pa-
tients (Dunah et al., 2002). These studies suggested that
a soluble form of mutant huntingtin may interfere with spe-
cific components of transcriptional machinery in early
stages of HD.
In addition to transcriptional deregulation, altered en-
ergy metabolism has been implicated in HD pathogenesis
(Browne and Beal, 2004). Striatal hypometabolism was
detected in asymptomatic HD subjects, and activities of
complexes of the electron transport chain were selectively
reduced in caudate and putamen of advanced-grade HD
patients (Antonini et al., 1996; Grafton et al., 1992; Kuwert
et al., 1993; Browne and Beal, 2004). Additional evidence
that energetic deficits may contribute to neurodegenera-
tion in HD came from studies showing that agents that
enhance energy production in the brain were neuroprotec-
tive (Browne and Beal, 2004). However, the mechanism by
which mutant huntingtin disrupts mitochondrial function
and oxidative metabolism remains unclear.
In this study we demonstrate that mutant huntingtin
interferes with energy metabolism by transcriptional re-
pression of PGC-1a (peroxisome proliferator-activated
receptor gamma coactivator-1 a). PGC-1a is a transcrip-
tional coactivator that regulates several metabolic pro-
cesses, including mitochondrial biogenesis and oxidative
phosphorylation (Puigserver and Spiegelman, 2003; FinckCell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc. 59
and Kelly, 2006). We show that PGC-1aplays an important
role in brain energy homeostasis and represents a key tar-
get of mutant huntingtin in the pathogenesis of HD.
RESULTS
Decreased Expression of PGC-1a in Striatum
of HD Brain
Recent findings suggest that striatum, the region most
affected in HD, may be particularly susceptible to disrup-
tion of energy metabolism caused by lack of PGC-1a (Lin
et al., 2004; Leone et al., 2005). To determine whether
PGC-1a expression may be altered in the striatum, we ex-
amined PGC-1amRNA in postmortem brain samples from
presymptomatic HD patients. We found a 30% decrease
of PGC-1a mRNA in the caudate nucleus of striatum,
whereas no significant changes in PGC-1a expression
were detected in the hippocampus or cerebellum in these
brain samples (Figure 1A). These results indicate that
PGC-1a expression is specifically decreased in the cau-
date, the first region affected in HD.
To examine whether PGC-1a downregulation leads to
alterations in the expression of genes involved in energy
metabolism, we first analyzed mRNA expression in the
striatum of PGC-1a knockout (KO) mice by microarrays.
Using gene-set enrichment analysis (GSEA), we found
that metabolic pathways involved in mitochondrial func-
tion were among the most significantly decreased in
PGC-1a KO striata (Figure S1A) (Subramanian et al., 2005).
Comparisons of pathways significantly downregulated in
PGC-1a KO mice with those downregulated in striata
from early-stage human HD revealed several common
pathways involving oxidative phosphorylation, mitochon-
drion, and the electron transport chain (Figure 1B) (Hodges
et al., 2006). Decreased expression of a subset of mito-
chondrial genes in human HD brain was confirmed by
real-time PCR (Figure S1B). These findings suggest that re-
duced expression of PGC-1a and its mitochondrial targets
may represent an early dysfunction in HD pathogenesis.
The striatum comprises approximately 90% medium
spiny projection neurons (MSN) and 10% aspiny interneu-
rons. In HD, medium spiny neurons degenerate whereas
striatal interneurons are spared, but the molecular mech-
anism of this preferential neuronal vulnerability is unknown
(Ferrante et al., 1985). Since we find that the levels of PGC-
1a are decreased in HD striatum, we used laser capture
microdissection (LCM) and quantitative real-time PCR to
analyze the expression of PGC-1a in individual striatal
MSN or nNOS interneurons. When compared with normal
mice, PGC-1a levels were decreased 5.6-fold in MSN iso-
lated from HD knockin (KI) mice (Menalled et al. 2003)
(Figure 1C). In contrast, PGC-1a was increased by 47-
fold in HD interneurons, as compared with normal striatal
interneurons (Figure 1D). These results suggest that
decreased expression of PGC-1a may contribute to in-
creased vulnerability of MSN observed in HD, whereas
nNOS interneurons may be protected by high levels of
PGC-1a.60 Cell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc.To further examine the function of PGC-1a in the con-
text of HD, we next analyzed levels of PGC-1a in a well-
established model of striatal neuronal cell lines generated
from HD KI mice (Trettel et al., 2000). These cell lines
(STHdhQ111) express endogenous mutant huntingtin and
display mutant phenotype, including decreased cAMP
synthesis and reduced ATP levels consistent with altered
energy metabolism (Gines et al., 2003). We compared
expression of PGC-1a and its mitochondrial targets in
wild-typeSTHdhQ7 and mutantSTHdhQ111 cells and found
that expression of both PGC-1a and mitochondrial genes
such as cytochrome C and COXIV were significantly de-
creased in STHdhQ111 cells (Figures 1E and 1F). PGC-1a
mRNA level was reduced approximately 10-fold in mutant
cells compared to the wild-type control. These results
suggest that decreased levels of PGC-1a might play a
role in mediating energy defects in mutant STHdhQ111
striatal cells.
Mutant Huntingtin Inhibits CRE-Dependent
Transcription of PGC-1a Promoter
Recent findings suggest that mutant huntingtin may be
involved in the regulation of gene transcription as a co-
repressor (Dunah et al., 2002; Zhai et al., 2005; Sugars
and Rubinsztein, 2003). To elucidate the mechanisms
of PGC-1a downregulation observed in HD brain and
STHdhQ111 cells, we next investigated whether mutant
huntingtin may repress the PGC-1apromoter. The PGC-1a
promoter reporter, encompassing 2533 to +78 of the
mouse PGC-1a gene, was transfected into striatal cell
lines from the wild-type and HD mutant mice. A dramatic
inhibition of the reporter was observed in the mutant
cells (STHdhQ111) compared to the wild-type cells
(STHdhQ7) (Figure 2A). In order to examine whether mutant
huntingtin directly inhibits the reporter, wild-type cells
(STHdhQ7) were transfected with increasing concentra-
tions of normal and mutant huntingtin along with the
PGC-1a reporter. Transfected mutant huntingtin signifi-
cantly repressed the PGC-1a reporter in a dose-depen-
dent manner (Figure 2B), suggesting that mutant huntingtin
modulates the expression of the PGC-1a gene at the level
of transcription.
Since STHdhQ111 cells exhibit decreased cAMP levels
(Gines et al., 2003), we next investigated whether treat-
ment of these cells with cAMP could affect the PGC-1a
reporter activity. As shown in Figure 2C, treatment of
STHdhQ111 mutant cells with 8-bromo-cAMP was able to
significantly upregulate the activity of the PGC-1a re-
porter. Importantly, these effects were dependent on the
CRE binding site in the PGC-1a proximal promoter, which
is known to be critically important for PGC-1a regulation in
several tissues (Herzig et al. 2001). The reduced expres-
sion of PGC-1a mRNA in STHdhQ111 cells and upregula-
tion of the PGC-1a reporter by cAMP prompted us to
examine whether endogenous PGC-1amRNA was modu-
lated by cAMP in STHdhQ111 cells. Treatment of these
cells with cAMP significantly upregulated PGC-1a mRNA
levels (Figure 2D). Taken together, these results suggest
Figure 1. Decreased Levels of PGC-1a
mRNA in Human and Mouse HD Brain
(A) Total RNA was isolated from the caudate
nucleus, cerebellum, and hippocampus of the
postmortem brain tissues of presymptomatic
HD subjects and normal controls. Samples
were analyzed by quantitative real-time PCR
with gene-specific primers and normalized to
28S RNA. Graphs represent means ± SEM
of three independent experiments. *p < 0.01
versus control.
(B) Gene-set enrichment analysis reveals over-
lapping gene sets that are significantly de-
creased in striata of PGC-1a KO mice and HD
patients. Data sets with false discovery rate
(FDR) Q value% 0.25 are presented.
(C) PGC-1a mRNA is decreased in KI HD mice
(HD) medium spiny neurons (MSN) compared
to wild-type (WT) mice MSN. Left panel shows
Q-PCR analysis of PGC-1a mRNA in laser
capture microdissected (LCM) MSN from
12-month-old KI (n = 4) and wild-type mice
(n = 4). The bars represent means ± SEM fold
change normalized to control, **p < 0.0001
versus wild-type. Right panel shows methylene
blue-stained MSN before (a) and after dissec-
tion (b) and dissected MSN neurons attached
to a thermoplastic film (c).
(D) PGC-1a mRNA is increased in HD KI mice
nNOS interneurons compared to wild-type
nNOS interneurons. Analysis was performed as
in (C). The bars represent means ± SEM fold
change normalized to control, **p < 0.0001
versus wild-type.
(E) PGC-1a mRNA is decreased in mutant
STHdhQ111 striatal cell line. mRNA levels of
PGC-1a in wild-type STHdhQ7 and mutant
STHdhQ111 striatal cell lines were measured by
quantitative real-time PCR and normalized to
b-actin mRNA. Expression levels of endogenous
normal and mutant huntingtin were comparable as verified by Western blotting (not shown). Graphs represent means ± SEM of three independent
experiments. *p < 0.0001 versus control.
(F) PGC-1a and mitochondrial protein levels are decreased in mutant striatal cell lines. Western blotting was performed using 40 mg of total cell
extracts from STHdhQ7 and STHdhQ111 cell lines expressing endogenous normal (Q7/7) and mutant (Q111/111) huntingtin, respectively. Antibodies
specific for PGC-1a, cytochrome C oxidase complex IV subunit I (COX IV) and cytochrome C were used. b-actin was used as loading control.
Experiments were done in triplicate.that PGC-1a gene repression by mutant huntingtin in-
volves CRE-dependent transcription.
To examine the mechanism of regulation of the PGC-1a
promoter by mutant huntingtin in relevant target cells,
primary striatal neurons were transfected with PGC-1a
promoter reporter along with mutant or normal huntingtin.
Although huntingtin with normal glutamine repeats
(HttQ17) had no significant effect on the promoter activity,
mutant huntingtin (HttQ75) produced significant inhibition
by more than 75% compared to the normal huntingtin
(Figure 2E). To determine whether the inhibition of CRE-
mediated transcription was dependent on increased
levels of huntingtin relative to those of endogenous
CREB, we overexpressed CREB together with huntingtin.
We found that overexpression of CREB that is constitu-
tively active (Du et al., 2000) significantly reduced butdid not rescue the inhibitory effects of mutant huntingtin
on PGC-1a promoter reporter (Figure 2E). These effects of
CREB were dependent on the CRE site on the PGC-1a
promoter, because no significant effect was seen when
the CRE site was mutated (not shown).
We have previously shown that huntingtin interacts with
TAF4 at least in part in the context of TFIID complex and
that TAF4 plays a critical role in mediating mutant hunting-
tin effects on Sp1-driven gene transcription (Dunah et al.,
2002). In addition to its function in Sp1 transcription, TAF4
also mediates coupling of CREB to TFIID and the basal
transcriptional machinery (Saluja et al., 1998; Shimohata
et al., 2000). Therefore, we examined whether CREB/
TAF4 is required for maximal activity of the PGC-1a pro-
moter. As shown in Figure 2E, coexpression of TAF4 and
CREB resulted in complete reversal of huntingtin-inducedCell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc. 61
Figure 2. PGC-1a Promoter Activity Is
Repressed by Mutant Huntingtin in Stria-
tal Cells
(A) STHdhQ7 (Q7/7) and STHdhQ111 (Q111/111)
cells were transfected with a luciferase reporter
(PGC-1a-luc) encompassing the promoter re-
gion 2533 to +78 of mouse PGC-1a gene.
Relative reporter activities were normalized
to the activity of the promoter-less luciferase
reporter construct, pGL3-Basic. Expression
of endogenous huntingtin and b-actin was
determined by Western blotting. Graphs re-
present means ± SEM of three experiments.
*p < 0.0001 versus Q7/7.
(B) Striatal STHdhQ7 cells were transfected with
PGC-1a-Luc reporter along with varying
amounts (0.2 mg, 0.4 mg, and 0.8 mg) of plasmid
expressing full-length wild-type (HD17) or mu-
tant huntingtin (HD75). Expression of mutant
huntingtin, but not the wild-type, repressed
PGC-1a promoter activity in a dose-dependent
manner. Protein expression was verified by
Western blotting (shown below the graph).
*p < 0.0001 versus vector control.
(C) Cyclic-AMP treatment reversed the inhibi-
tion of PGC-1a promoter activity in mutant
STHdhQ111 striatal cells. STHdhQ111cells were
transfected with PGC 1a-luc as described in
(A) or PGC-1aCREmut-luc with the mutated
CRE site. Twenty-four hours after transfection,
the cells were treated with 0.5 mM 8-Bromo-
cAMP (8-Br-cAMP) and reporter activities
measured 24 hr later. Data were normalized
to b-galactosidase activity. The relative lucifer-
ase activity in cells transfected with the
wild-type PGC-1a-luc is arbitrarily shown as
100 ± SEM. Graphs show means ± SEM of at least three independent experiments. **p < 0.001 versus basal (black bar).
(D) Cyclic-AMP treatment induced endogenous PGC-1a mRNA expression in mutant striatal cells. STHdhQ111cells were treated with 0.5 mM
8-Br-cAMP for 16 hr and PGC-1a mRNA levels analyzed by real-time PCR. b-actin mRNA was used for normalization. Graphs show means ± SEM
of three independent experiments. *p < 0.01 versus untreated control (Ctl).
(E) Mutant huntingtin-mediated repression of PGC-1a promoter is prevented by overexpression of CREB and TAF4. Primary striatal neurons were
transfected with PGC-1a-luc, along with plasmids expressing full-length normal (HD17) or mutant huntingtin (HD75). Coexpression of constitutively
active CREB and TAF4 completely reversed mutant huntingtin (HD75)-induced inhibition of PGC-1a promoter activity, whereas TAF4DC that lacks
the C-terminal 250 amino acids did not significantly affect PGC-1a promoter activity. The relative reporter activity in cells transfected with vector alone
is arbitrarily shown as 100 ± SEM. Graphs show means ± SEM of at least three independent experiments. Xp < 0.001 versus vector, *p < 0.05 versus
HD75, and **p < 0.001 versus HD75.inhibition of PGC-1a promoter activity, indicating that mu-
tant huntingtin affects the CREB/TAF4 transcriptional
pathway. TAF4 interacts with other TAFs primarily via its
C-terminal domain, suggesting the importance of this do-
main for the interactions of TAF4 with the TFIID complex
(Asahara et al., 2001). To examine whether the effects of
CREB and TAF4 on PGC-1a were dependent on intact
C-terminal domain of TAF4, we coexpressed the C-termi-
nal deletion mutant of TAF4 in primary striatal neurons. No
significant effect of TAF4 on PGC-1a promoter activity
was observed when the C terminus of TAF4 was deleted,
suggesting that this domain is required to reverse the re-
pression of the PGC-1a promoter by mutant huntingtin
(Figure 2E).
Together, these results show that mutant huntingtin in-
hibits transcription of PGC-1a by interfering with the
CREB/TAF4 acting on the PGC-1a promoter.62 Cell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc.Mutant Huntingtin Is Associated with PGC-1a
Promoter in Striatal Cells and HD Mice
We next used chromatin immunoprecipitation (ChIP) assay
to determine occupancy of transcription factors at PGC-1a
gene in striatal tissues of wild-type and HD KI mice
(Figure 3A), R6/2 HD mice (Figure 3B), and in striatal cells
derived from wild-type and HD KI mice (Figure 3C). Unex-
pectedly, we found mutant huntingtin protein to occupy
the PGC-1a promoter region in the brains and cells of HD
KI mice (Figures 3A and 3C), while presence of wild-type
huntingtin was not detected at this promoter. By contrast,
occupancy by CREB and TAF4 at the PGC-1a promoter
was not substantially altered in wild-type and HD KI cells.
To investigate whether increased occupancy of PGC-1a
promoter by mutant huntingtin results in altered PGC-1a
transcription in vivo, RNA polymerase II chromatin immu-
noprecipitations (RNAPol-ChIP) were performed. This
Figure 3. Mutant Huntingtin Occupies
PGC-1a Promoter in Mutant Striatal Cells
and HD Mice
(A) Brain homogenates of wild-type and HD KI
(CAG 140) mice were prepared and ChIP as-
says of the PGC-1a promoter region performed
with indicated antibodies. Presence of mutant
huntingtin (Htt), but not wild-type, was de-
tected at the PGC-1a promoter. Graphs show
means ± SEM of three independent experi-
ments.*p < 0.0001 versus wild-type, Xp 0.05
versus wild-type.
(B) RNAPol-ChIP assay of the PGC-1a coding
region using wild-type and R6/2 mouse brain
tissues showed reduced rate of transcription
of the PGC-1a gene in vivo. PCR primers corre-
spond to the PGC-1agene-coding region (+655
to +778) downstream of the transcription start
site. Graphs show means ± SEM of three
independent experiments. **p < 0.001 versus
wild-type.
(C) ChIP analysis of the PGC-1a and dopamine
receptor D2 gene promoter in mouse striatal
cells expressing wild-type huntingtin (W,
STHdhQ7/Q7) or mutant huntingtin (M,
STHdhQ111/Q111). Formaldehyde cross-linked
chromatin was immunoprecipitated with
indicated antibodies, and the precipitated material was amplified by PCR using primers specific for each promoter region and stained with ethidium
bromide on an agarose gel. A downstream region of the D2 gene was used as a control. Input lanes represent 0.5, 1% (lanes 1, 2) and 0.1, 0.5%
(lanes 3, 4) of chromatin.procedure detects the presence of RNA polymerase II
within the coding region of the target gene as a way of mea-
suring active transcription (Sandoval et al., 2004). Using
this approach, we found decreased transcription of
PGC-1a gene in R6/2 mouse brain as compared to normal
littermates (Figure 3B). When genes that are not altered in
HD mice, such as albumin, were analyzed by RNAPol-
ChIP, no change was observed in polymerase II binding
between the normal and HD mice (data not shown).
These results suggest that mutant huntingtin associates
with chromatin and interferes with the activation functions
of promoter bound transcription factors CREB and TAF4
to repress transcription. Interestingly, we observed occu-
pancy of wild-type huntingtin at a different promoter, the
dopamine D2 receptor gene promoter, indicating that
wild-type huntingtin may target certain genes to regulate
transcription (Figure 3C). These results represent the first
evidence that wild-type and mutant huntingtin occupy
promoter regions of endogenous neuronal target genes
and suggest that differential targeting of huntingtin may
help explain specific changes in gene expression observed
in HD.
PGC-1a Expression Protects against Mutant
Huntingtin-Induced Mitochondrial
Dysfunction and Striatal Toxicity
Since PGC-1a regulates mitochondrial respiration (Puig-
server and Spiegelman, 2003), decreased levels of PGC-
1a may contribute to mitochondrial dysfunction that is
characteristic of striatal HD cells (Gines et al., 2003). Wetherefore directly assessed mitochondrial energy metabo-
lism in wild-type and mutant STHdhQ111 cells using the
MTS assay. This method is based on the reduction of the
soluble tetrazolium salt to insoluble formazan product by
mitochondrial succinic dehydrogenase. The results re-
vealed that formazan production was significantly reduced
by approximately 35% in mutant cells compared with wild-
type cells (Figure 4A). Importantly, recombinant adenovi-
rus-mediated expression of PGC-1a in STHdhQ111 cells
significantly reversed the mitochondrial defect as deter-
mined by MTS assay, suggesting that upregulation of
PGC-1a can rescue the effect of mutant huntingtin on
mitochondrial function.
We next analyzed primary striatal cultures that recapit-
ulate features of the neurodegenerative process that oc-
curs in HD. Transfection of full-length mutant huntingtin
(HD75) induced neuronal cell death, whereas the wild-
type huntingtin did not show any toxic effects, as previ-
ously reported (Figure 4B) (Saudou et al., 1998; Dunah
et al., 2002). However, when mutant huntingtin is coex-
pressed in striatal neurons together with PGC-1a, the tox-
icity of mutant huntingtin was significantly abrogated
(Figure 4B), suggesting that expression of PGC-1a in stria-
tal neurons substantially rescues the deleterious effects of
mutant huntingtin.
Since our data showed that CREB and TAF4 were able
to completely reverse the repressive effects of mutant
huntingtin on PGC-1a promoter activity (Figure 2E), we
tested whether striatal neurons could be protected
against mutant huntingtin by transfecting constitutivelyCell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc. 63
active CREB along with TAF4. We found that coexpres-
sion of CREB and TAF4 resulted in statistically significant
protection of striatal cells from the effects of mutant hun-
tingtin (Figure 4C). Coexpression of CREB with TAF4 lack-
ing its C-terminal domain failed to block huntingtin-in-
duced cell death (data not shown), suggesting that intact
interactions of TAF4 with TFIID and other factors are re-
quired for its protective function. Together, these data
demonstrate that CREB/TAF4-dependent regulation of
PGC-1a gene, at least in part, mediates the protective
effects of PGC-1a in striatal neurons.
Figure 4. Overexpression of PGC-1a Protects against Mutant
Huntingtin-Induced Mitochondrial Dysfunction and Striatal
Toxicity
(A) Overexpression of PGC-1a partially rescued the decreased mito-
chondrial metabolic activity in mutant STHdhQ111cells (Q111/111) as
measured by MTS assay. Infection of Q111/111 cells with recombinant
adenovirus-expressing PGC-1a led to significant upregulation of MTS
activity. Expression of PGC-1awas verified by Western blotting and by
real-time PCR. Reduction of MTS by cells was measured as units of
absorbance at optical density 490 nm. Graphs show means ± SEM
of at least three independent experiments. X p < 0.01 versus Q7/7 cells.
(STHdhQ7). *p < 0.01 versus Q111/111 transfected with control
adenovirus.
(B) Overexpression of PGC-1a protected against mutant huntingtin-
induced striatal toxicity. Primary striatal cultures were transfected
with PGC-1a along with full-length mutant HD75 or wild-type HD17
huntingtin. Mutant huntingtin-induced cell death was significantly
prevented by the overexpression of PGC-1a. Expression levels of
transfected constructs were verified by quantitative immunocyto-
chemistry. Cell nuclei were stained with Hoechst 33258 and con-
densed and/or fragmented nuclei scored as apoptotic using confocal
microscope. Graphs represent means ± SEM of three independent ex-
periments. Xp < 0.001 compared to HD17 and *p < 0.001 versus HD75.
(C) CREB and TAF4 together protect against mutant huntingtin-
induced striatal toxicity. Primary striatal cultures were transfected
and analyzed as in (B). Mutant huntingin-induced cell death was
significantly prevented by overexpression of the constitutively active
CREB and TAF4. Graphs represent means ± SEM of three inde-
pendent experiments. Xp < 0.001 compared to HD17 and *p < 0.001
versus HD75.64 Cell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc.Lentiviral-Mediated Delivery of PGC-1a in the
Striatum Provides Neuroprotection in the
Transgenic Mouse Model of HD
To further test our hypothesis that PGC-1amay be protec-
tive in HD, lentiviral vector expressing PGC-1awas directly
administered into the striatum of R6/2 transgenic HD mice.
We chose to analyze the R6/2 model because it has a well-
characterized progressive phenotype that recapitulates
many of the neuropathological features observed in HD
patients, such as striatal atrophy, cellular atrophy, and
huntingtin-positive aggregates (Ferrante et al., 2000).
The striata of 5.5 week-old R6/2 mice were injected with
lentiviral vector expressing PGC-1a (Figures 5A and 5B).
Using unbiased stereological methods, neuronal volumes
were examined 3.5 weeks after the injection. When analyz-
ing a series of sections spanning the injected region of
striatum, a statistically significant increase in the mean
neuronal volume by 27.8% was observed in striata injected
with PGC-1aas compared to contralateral striata that were
not injected. No significant change in cell volume was ob-
served in neurons injected with control lentiviral vector ex-
pressing green fluorescent protein (GFP) (Figures 5C and
5D). Previous studies have demonstrated that R6/2 mice
exhibit progressive atrophy of striatal neurons from about
3 to 12 weeks of age with almost 40% overall decrease
in area measurements. In addition, at the age of 9 weeks,
when our analysis was performed, volumes of striatal neu-
rons in R6/2 mice decreased by about 30% compared to
littermate transgene-negative mice (Figure 5D, Ferrante
et al., 2000). Such atrophy of striatal neurons represents
a neuropathological feature in R6/2 mice that most closely
resembles neuropathology observed in human HD. Here
we show that administration of PGC-1a to R6/2 mice com-
pletely prevents neuronal atrophy in R6/2 mice. Moreover,
the findings in HD mice are in agreement with our studies in
cell culture showing that overexpression of PGC-1a pro-
tects striatal neurons from toxicity by mutant huntingtin.
Crossbreeding of HD KI Mice with PGC-1a KO Mice
Results in Behavioral and Striatal Abnormalities
in the HD Mice
The experiments described above demonstrated that ex-
pression of PGC-1a is neuroprotective in HD mice. We
next examined whether further downregulation of PGC-
1a leads to worsening of behavioral and neuropathologi-
cal abnormalities in HD KI mice that have 140 CAG repeats
inserted in the murine huntingtin gene. The 140 CAG KI
mice display very mild behavioral and neuropathological
abnormalities at baseline (Menalled et al., 2003). When
the KI mice were crossbred with PGC-1a KO mice (KI/
KO), a significant worsening of motor performance was
observed in the 6 month-old crossed mice as compared
to the KI or KO littermates (Figure 6A). To investigate
whether these behavioral abnormalities in the KI/KO
crossed mice were due to alterations in neuronal pathol-
ogy, we performed a neuropathological evaluation of
serial brain sections. Using a silver-staining technique
that detects degenerating neurons, we identified early
Figure 5. Lentiviral Delivery of PGC-1a in
the Striatum of R6/2 Transgenic HD Mice
Completely Prevents Atrophy of Striatal
Neurons
(A) Expression of lentiviral vectors in the stria-
tum of R6/2 mice 3 weeks after injection. The
highest density of the transduced cells was
around the injection site (box). Approximately
10% of the striatum showed high expression
of lentiviral vectors encoding PGC-1a and
GFP as determined by staining with antibodies
against His-tag or GFP.
(B) Striatal sections immunostained with anti-
body recognizing the His-tag of lenti-PGC-1a
(green). More than 90% transduced cells dis-
played neuronal morphology.
(C) Representative striatal sections stained
with cresyl violet showing neuronal atrophy
(arrows) in noninjected R6/2 striatum (HD) rela-
tive to the contralateral side injected with
lenti-PGC-1a (HD+PGC-1a).
(D) Neuronal volumes were decreased by
29.2% in 9 week-old R6/2 striata compared
to controls (WT). Expression of lenti-PGC-1a
in R6/2 striata (HD+PGC-1a) led to increased
neuronal volumes by 27.8% compared to non-
injected R6/2 neurons (HD) and 35.1% com-
pared to R6/2 neurons injected with lenti-
GFP. The striata of R6/2 mice were injected
with viral constructs at 5.5 weeks and neuronal
volumes analyzed at 9 weeks of age using un-
biased stereological methods (MicroBright-
Field). Average sum of 795 transduced neurons
was examined per animal. Y axis shows mean
neuronal volumes 5.44 ± 0.717 (WT), 4.21 ±
0.552 (HD), 3.98 ± 0.456 (HD+GFP), and 5.38 ±
0.679 (HD+PGC-1a) 3 107 mm3. Graphs
represent means ± SEM of at least five animals
per group. Xp < 0.01 compared to wild-type
and *p < 0.01 compared to HD.neurodegenerative changes in the medial septal nucleus
and striatum of the 3 month-old KI/KO crossed mice
(Figure 6B). Moreover, a significant reduction in striatal
neuronal volumes was observed in the 6 month-old KI/
KO mice compared to littermate KI mice (Figure 6C).
These results further demonstrate that downregulation of
PGC-1a contributes to accelerated degeneration of stria-
tal neurons in HD.
We next examined whether decreased expression of
PGC-1a rendered the crossed mice more susceptible to
neurotoxin 3-nitropropionic acid (3-NP) known to induce
HD-like symptoms. 3-NP is a complex II inhibitor that se-
lectively induces striatal lesions when administered sys-
temically in humans, primates, and rodents. The distribu-
tion and pathology of the 3-NP-induced striatal lesions
closely resemble those seen in HD (Browne and Beal,
2004). We injected 3-NP directly into the striata of the
crossed KI/KO and KI HD mice. Administration of 3-NP
produced significantly larger striatal lesions and in-
creased number of degenerating neurons in the KI/KO
mice compared to the KI mice (Figure 6D). These resultsfurther support the importance of PGC-1a in protection
of striatal neurons from metabolic stress and neurode-
generation in HD.
DISCUSSION
Abnormalities in striatal energy metabolism in HD repre-
sent an important part of the early pathogenesis of this
disease (Koroshetz et al., 1997; Browne and Beal, 2004).
For example, decreased striatal metabolism occurs in
presymptomatic HD patients, years before the onset of
clinical symptoms, indicating that striatal neurons are par-
ticularly vulnerable to disruptions of mitochondrial func-
tion (Browne and Beal, 2004). This conclusion is under-
scored by the fact that the PGC-1a KO mice show most
striking lesions in the striatum despite the uniform ab-
sence in PGC-1a expression in all brain regions (Lin
et al., 2004; Leone et al., 2005). We found decreased ex-
pression of a number of mitochondrial genes in striata of
the PGC-1a KO mice, suggesting that alterations in mito-
chondrial function may be responsible for the observedCell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc. 65
Figure 6. Crossbreeding of HD KI Mice
(KI) with PGC-1a KO Mice (KO) Leads to
Behavioral Abnormalities and Increased
Neurodegeneration in the Crossed Mice
(KI/KO)
(A) Rotarod performance is severely impaired in
KI/KO mice (HD(CAG)140+//PGC-1a+/). Wild-
type (WT), HD(CAG)140+/ (KI), PGC-1a+/ (KO),
and KI/KO mice were tested for performance
in four trials per day for 4 consecutive days
(n = 20 per group). Bars represent means ±
SEM latencies to fall. *p = 0.005 versus KI mice.
(B) Early neuronal degeneration appears in the
striatum and septum of KI/KO mice. Brain sec-
tions from 3 month-old KI (a and c) and KI/KO (b
and d) mice were silver stained to detect disin-
tegrative neuronal processes (arrows) from de-
generating neurons in medial septal nucleus (b)
and striatum (d) of the KI/KO mice. No degener-
ation was observed in the septum (a), striatum
(c), or any other brain region in the KI mice.
(C) Striatal neuronal volumes were significantly
decreased in 6 month-old KI/KO mice. Neuro-
nal volumes were analyzed as described in
Figure 5D. Graphs represent means ± SEM vol-
umes from at least five animals in each group.
*p < 0.01 compared with KI.
(D) Loss of PGC-1a gene leads to increased
susceptibility of HD mice to 3-nitropropionic
acid (3-NP). Striata of the KI (a and c) and KI/
KO (b and d) mice were injected with 3-NP
(75 nmol) and analyzed 24 hr later by Nissl (a
and b) and Fluorojade C staining (c and d). Ad-
ministration of 3-NP resulted in increased size
of the lesions (compare a and b) and the num-
ber of degenerating neurons (compare c and d)
in the KI/KO mice as compared with the KI
mice. Stereological analysis of the lesion
showed significantly increased volumes in the
KI/KO compared to KI mice (n = 8 in each
group). Bars represent means ± SEM striatal
lesion volume. *p< 0.005 versus KI.neuropathology in these mice. Although the neuropatho-
logic changes observed in the PGC-1a KO mice appear
nonspecific compared to those found in HD, it is striking
that the KO mice show such prominent abnormalities in
the striatum, the region most affected in HD.
In this study we demonstrate that PGC-1a expression is
selectively and significantly downregulated in HD striatal
cells and tissues. Our results suggest that a possible
mechanism for the observed downregulation of PGC-1a
involves transcriptional repression of PGC-1a promoter
by mutant huntingtin. We find that mutant huntingtin
represses CRE-mediated transcription of PGC-1a by
interfering with the CREB/TAF4 transcriptional pathway
in striatal neurons. Interestingly, ChIP analysis revealed
that mutant but not wild-type huntingtin was found asso-
ciated with the endogenous PGC-1a promoter, suggest-
ing that the mutant protein disrupts the function of
promoter bound transcription factors. Reduced CRE-
dependent transcription has been previously observed66 Cell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc.as an early abnormality in HD pathogenesis, but the target
genes of the CRE-dependent transcription in HD have not
been determined (Gines et al., 2003; Sugars and Rubinsz-
tein, 2003). Moreover, ablation of CREB and CREM in the
postnatal CNS produces a progressive neurodegenera-
tion in striatum that is reminiscent of HD, suggesting that
CREB may play an important role in HD pathogenesis
(Mantamadiotis et al., 2002). Mutant huntingtin has been
shown previously to directly repress transcription of
Sp1-driven genes by uncoupling the interactions of acti-
vator (Sp1) with the coactivator TAF4 (Dunah et al.,
2002). Since both Sp1 and CREB interact with TAF4, we
think these interactions are directly targeted by mutant
huntingtin in certain promoter context. We found that
huntingtin interacts with both the glutamine-rich central
domain and the C-terminal domain of TAF4 and that the
C-terminal domain is required for protection against hun-
tingtin-induced transcriptional dysregulation and neuronal
cell death (Figure 2E, Dunah et al., 2002). The conserved
C-terminal domain of TAF4 participates in a number of
protein-protein interactions, including several TAFs in
the TFIID complex (Furukawa and Tanese, 2000; Asahara
et al., 2001). These findings and the recent report that
atrophin, which causes another polyglutamine disease
(DRPLA), also binds to the C-terminal domain of TAF4
(Shimohata et al., 2000), suggest that TAF4, probably in
the context of TFIID, represents a key target of polyglu-
tamine proteins such as huntingtin.
Interestingly, we find that PGC-1a levels were de-
creased in MSN but upregulated in nNOS interneurons iso-
lated from HD mice. It is well established that striatal MSN
selectively degenerate whereas nNOS interneurons sur-
vive in HD (Ferrante et al., 1985). Previous studies showed
that mutant huntingtin accumulates in the nucleus of MSN
but not in nNOS interneurons (Wheeler et al., 2000). Since
our ChIP data suggest that inhibition of PGC-1a transcrip-
Figure 7. Model for Regulation of PGC-1a in Huntington’s
Disease (HD)
In a normal state, PGC-1a regulates metabolic programs and main-
tains energy homeostasis in the CNS (upper panel). In HD, mutant hun-
tingtin interferes with CREB and TAF4 regulation of PGC-1a transcrip-
tion that leads to inhibited expression of PGC-1a. Inhibition of PGC-1a
expression limits the ability of the vulnerable neurons to adequately re-
spond to energy demands in HD (lower panel). Direct toxic effects of
mutant huntingtin on mitochondria and other energy-dependent neu-
ronal processes such as axonal transport may worsen when protective
function of PGC-1a is inhibited.tion in HD involves recruitment of mutant huntingtin to
PGC-1a promoter, we think that the absence of mutant
huntingtin in the nucleus of interneurons may partly explain
increased levels of PGC-1a mRNA in these cells.
Here, a model is proposed where mutant huntingtin
affects mitochondrial function by interfering with PGC-
1a gene transcription (Figure 7). We hypothesize that in
the normal state, PGC-1a regulates metabolic programs
and maintains energy homeostasis in the CNS, whereas
inhibition of PGC-1a transcription by mutant huntingtin
leads to defects in energy metabolism and dysfunction
of neurons that are most vulnerable to metabolic stress,
such as striatal neurons. Our results indicate that inhibition
of PGC-1a function by mutant huntingtin limits the ability
of striatal neurons to adequately respond to metabolic de-
mands in HD. Such disruption in energy homeostasis in
HD may lead to alteration of multiple cellular functions
and ultimately results in neurodegeneration. In addition,
mutant huntingtin directly targets cellular processes with
high energy requirements such as axonal transport (Guna-
wardena et al., 2003; Szebenyi et al., 2003; Gauthier et al.,
2004). Moreover, expanded polyglutamines alter mito-
chondrial membrane depolarization, making cells more
vulnerable to metabolic stress (Panov et al., 2002; Brusto-
vetsky et al., 2003; Choo et al., 2004). Such direct toxic ef-
fects of mutant huntingtin may become more pronounced
when the protective function of PGC-1a is inhibited (Fig-
ure 7). It will be of interest to determine whether stimula-
tion of the pathways of energy metabolism controlled by
PGC-1a could provide potential clinical benefit at an early
stage of HD.
EXPERIMENTAL PROCEDURES
Striatal Cell Lines and Primary Striatal Neurons
Immortalized wild-type STHdhQ7/Q7 striatal neuronal progenitor cells
expressing endogenous normal huntingtin and homozygous mutant
STHdhQ111/Q111 lines expressing endogenous mutant huntingtin with
111 glutamines were cultured as described (Gines et al., 2003). Re-
combinant adenoviral vector containing FLAG-tagged PGC-1a (Ad-
Flag-PGC-1a) and PGC-1a-luc were generously provided by Bruce
Spiegelman lab. Primary striatal neurons were cultured from E18
Sprague-Dawley rats as described (Dunah et al., 2002). For measure-
ments of neuronal cell death, neurons were scored as apoptotic if they
had pyknotic or fragmented nuclei. Cells were transfected using Lipo-
fectamine 2000 (Invitrogen) as described (Dunah et al., 2002). The
PGC-1a promoter-luciferase reporter was described previously
(Handschin et al., 2003). Luciferase activity was determined 48 hr after
transfection using the luciferase assay kit (Promega) and normalized to
b-galactosidase activity (Clontech). The relative activity was normal-
ized to the activity of the promoter-less reporter, pGL3-Basic (Prom-
ega). The metabolic activity of mitochondria was assayed by using
a modified MTS assay kit (Promega).
Quantitative Real-Time PCR and Immunoblot Analysis
Total RNA was isolated from cultured cells or brain tissues using
RNeasy Lipid Tissue kit (Qiagen). Postmortem human brain tissues
were from asymptomatic carriers of HD mutation (CAG 45-57, Grade 0)
and age- and gender-matched normal controls with similar postmor-
tem interval. R6/2 transgenic HD mice were obtained from Jackson
Laboratory. RNA was analyzed by quantitative real-time PCR using
SYBR Green (Applied Biosystems). Primer sequences used in allCell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc. 67
PCR experiments are listed in Table S1. Western blots were performed
as described (Dunah et al., 2002). The blots were probed with the
following primary antibodies: PGC-1a (K-15) (sc-5816, Santa Cruz
Biotechnology), Oxphos Complex IV subunit I (1D6, BD Biosciences
Pharmingen) Cytochrome C (7H8.2C12, Chemicon), actin (sc-1616,
Santa Cruz).
Gene-Expression Profiling
Total RNA was extracted from striata of PGC-1a KO mice and litter-
mate controls and analyzed by RNA 6000 Nano LabChip kit on
a 2100 Bioanalyzer (Agilent Technologies) to ensure integrity of RNA.
The RNA was processed according to the standard Affymetrix proto-
col and analyzed using the Mouse Genome 430 2.0 Gene Chips. The
functional correlation of gene sets systemically altered in expression
profiles of PGC-1a KO mice and a previously published human HD
expression (Hodges et al., 2006) was assessed using Gene Set Enrich-
ment Analysis (Subramanian et al., 2005).
ChIP Assay
Homogenized brain tissues were forced through a 70 mm cell-strainer
cap followed by incubation in Dulbecco’s modified Eagle medium
containing 1% formaldehyde. The samples were sonicated with a
Fisher sonicator for 123 15 s cycles at 60% output power, the lysates
centrifuged at 13,000 3 g for 10 min, and diluted 10-fold in ChIP dilu-
tion buffer. ChIP assay was performed following published procedures
(Takahashi et al, 2000). RNAPol-ChIP was carried out as described
(Sandoval et al., 2004). Primer sequences are listed in Table S1.
Crossbreeding and Analysis of HD Mice
PGC-1a KO mice (Leone et al. 2005) were crossed with HD KI mice
(Menalled et al., 2003) to obtain all possible viable genotypes, as deter-
mined by PCR with tail-tip DNA and sequencing to confirm genotype
and CAG repeat length. Recombinant lentiviral vectors expressing
PGC-1a were generated as described (Sena-Esteves et al. 2004)
and stereotaxically injected into the striatum of 5.5 week-old R6/2
mice. After 3.5 weeks serial brain sections were examined stereologi-
cally as described (Ferrante et al., 2000). Briefly, unbiased estimates of
number–weighted mean neuronal volumes were determined using the
optical fractionator and nucleator probes (Micro BrightField; Williston,
VT). Objective used to estimate the volumes of striatal cells was 363;
counting frame 503 50 mm, sampling grid 1003 100 (x and y); average
section thickness after histological processing, 7.0 mm (top guard
zone, 3mm, and bottom, 4mm); average sum of neurons analyzed per
animal, 795. ANOVA with post hoc t tests was performed to identify
significant differences. Silver staining of sections was performed as
described in the FD Neurosilver kit (FD Neurotechnologies,). Fluoro-
Jade C staining was performed according to the supplier’s manual
(HistoChem). Motor performance was performed using the rotarod ap-
paratus (Economex Rotarod, Columbus Instruments). The mice were
pretrained on the rotarod for five trials at low speed for up to 120 sec
and tested for four trials per day for 4 consecutive days. Rotating rod
underwent a linear acceleration from 4 to 40 rpm over the first 6 min
of the trial and then remained at maximum speed for the remaining 4
min. For the 3-NP experiments, a total of 75 nmol of 3-NP in a volume
of 1 ml was injected into striatum at a rate of 0.2 ml/min. All animals were
sacrificed 24 hr after 3-NP injections and brains postfixed in PLP fixa-
tive for 16 hr and then immersed in 25% sucrose in 0.1 M PB, pH 7.4 for
48 hr. Laser capture microdissection was performed as described
(Zucker et al. 2005). Briefly, coronal 8 mm striatal sections from four
CAG140 KI and four wild-type mice were cut on a cryostat and
thaw-mounted on non-coated glass slides. For visualization of MSN
or nNOS positive interneurons, sections were stained with methylene
blue or rabbit anti-nNOS antibody (N7155, Sigma), respectively. At
least 1000 striatal neurons per group were dissected using the PixCell
II LCM instrument and total RNA isolated by PicoPure RNA kit
(Arcturus).68 Cell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc.Supplemental Data
Supplemental Data include one figure, one table, and experimental
procedures and can be found with this article online at http://www.
cell.com/cgi/content/full/127/1/59/DC1/.
ACKNOWLEDGMENTS
We thank Hongwei Jin for help with stereotaxic surgery; Geoff Greene
from MicroBrightField, Inc. and Jonathan H. Fox for help with stereol-
ogy experiments; Daniel P. Kelly and Teresa C. Leone for PGC-1a KO
mice and helpful discussions; Fu Du for help with silver staining; and
Jiandie Lin, Bruce Spiegelman, Anne B. Young, Tong Lin, Katrin Lin-
denberg, Robert Ferrante, Birgit Zucker, and Nicole Deglon for helpful
discussions or comments on the manuscript. We thank Marcy
MacDonald for striatal cell lines and Harvard Brain Tissue Resource
Center, Jean-Paul Vonsattel, and Kathy Newell for human postmortem
brain tissues. This work was supported by R01NS050352 and
P01NS045242 (D.K.). F.B. was supported by Fulbright Fellowship.
Received: June 1, 2006
Revised: August 15, 2006
Accepted: September 8, 2006
Published: October 5, 2006
REFERENCES
Alba, M.M., and Guigo, R. (2004). Comparative analysis of amino acid
repeats in rodents and humans. Genome Res. 14, 549–554.
Antonini, A., Leenders, K.L., Spiegel, R., Meier, D., Vontobel, P., Wei-
gell-Weber, M., Sanchez-Pernaute, R., de Yebenez, J.G., Boesiger, P.,
Weindl, A., and Maguire, R.P. (1996). Striatal glucose metabolism and
dopamine D2 receptor binding in asymptomatic gene carriers and
patients with Huntington’s disease. Brain 11, 2085–2095.
Asahara, H., Santoso, B., Guzman, E., Du, K., Cole, P.A., Davidson, I.,
and Montminy, M. (2001). Chromatin-dependent cooperativity be-
tween constitutive and inducible activation domains in CREB. Mol.
Cell. Biol. 21, 7892–7900.
Browne, S.E., and Beal, M.F. (2004). The energetics of Huntington’s
disease. Neurochem. Res. 29, 531–546.
Brustovetsky, N., Brustovetsky, T., Purl, K.J., Capano, M., Crompton,
M., and Dubinsky, J.M. (2003). Increased susceptibility of striatal mito-
chondria to calcium-induced permeability transition. J. Neurosci. 23,
4858–4867.
Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J., and Lesort, M.
(2004). Mutant huntingtin directly increases susceptibility of mitochon-
dria to the calcium-induced permeability transition and cytochrome
c release. Hum. Mol. Genet. 13, 1407–1420.
Du, K., Asahara, H., Jhala, U.S., Wagner, B.L., and Montminy, M.
(2000). Characterization of a CREB gain-of-function mutant with con-
stitutive transcriptional activity in vivo. Mol. Cell. Biol. 20, 4320–4327.
Dunah, A.W., Jeong, H., Griffin, A., Kim, Y.M., Standaert, D.G., Hersch,
S.M., Mouradian, M.M., Young, A.B., Tanese, N., and Krainc, D. (2002).
Sp1 and TAFII130 transcriptional activity disrupted in early Hunting-
ton’s disease. Science 296, 2238–2243.
Ferrante, R.J., Kowall, N.W., Beal, M.F., Richardson, E.P., Jr., Bird,
E.D., and Martin, J.B. (1985). Selective sparing of a class of striatal
neurons in Huntington’s disease. Science 230, 561–563.
Ferrante, R.J., Andreassen, O.A., Jenkins, B.G., Dedeoglu, A.,
Kuemmerle, S., Kubilus, J.K., Kaddurah-Daouk, R., Hersch, S.M.,
and Beal, M.F. (2000). Neuroprotective effects of creatine in a trans-
genic mouse model of Huntington’s disease. J. Neurosci. 20, 4389–
4397.
Finck, B.N., and Kelly, D.P. (2006). PGC-1 coactivators: inducible reg-
ulators of energy metabolism in health and disease. J. Clin. Invest. 116,
615–622.
Furukawa, T., and Tanese, N. (2000). Assembly of partial TFIID com-
plexes in mammalian cells reveals distinct activities associated with
individual TATA box-binding protein-associated factors. J. Biol.
Chem. 275, 29847–29856.
Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Ran-
gone, H., Cordelieres, F.P., De Mey, J., MacDonald, M.E., Lessmann,
V., Humbert, S., and Saudou, F. (2004). Huntingtin controls neurotro-
phic support and survival of neurons by enhancing BDNF vesicular
transport along microtubules. Cell 118, 127–138.
Gines, S., Seong, I.S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J.F.,
Wheeler, V.C., Persichetti, F., and MacDonald, M.E. (2003). Specific
progressive cAMP reduction implicates energy deficit in presymp-
tomatic Huntington’s disease knock-in mice. Hum. Mol. Genet. 12,
497–508.
Grafton, S.T., Mazziotta, J.C., Pahl, J.J., St George-Hyslop, P., Haines,
J.L., Gusella, J., Hoffman, J.M., Baxter, L.R., and Phelps, M.E. (1992).
Serial changes of cerebral glucose metabolism and caudate size in
persons at risk for Huntington’s disease. Arch. Neurol. 49, 1161–1167.
Gunawardena, S., Her, L.S., Brusch, R.G., Laymon, R.A., Niesman, I.R.,
Gordesky-Gold, B., Sintasath, L., Bonini, N.M., and Goldstein, L.S.
(2003). Disruption of axonal transport by loss of huntingtin or expres-
sion of pathogenic polyQ proteins in Drosophila. Neuron 40, 25–40.
Handschin, C., Rhee, J., Lin, J., Tarr, P.T., and Spiegelman, B.M.
(2003). An autoregulatory loop controls peroxisome proliferator-
activated receptor gamma coactivator 1alpha expression in muscle.
Proc. Natl. Acad. Sci. USA 100, 7111–7116.
Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Ru-
dolph, D., Schutz, G., Yoon, C., Puigserver, P., et al. (2001). CREB
regulates hepatic gluconeogenesis through the coactivator PGC-1.
Nature 413, 179–183.
Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T.,
Hughes, G., Elliston, L.A., Hartog, C., Goldstein, D.R., Thu, D., et al.
(2006). Regional and cellular gene expression changes in human
Huntington’s disease brain. Hum. Mol. Genet. 15, 965–977.
Koroshetz, W.J., Jenkins, B.G., Rosen, B.R., and Beal, M.F. (1997). En-
ergy metabolism defects in Huntington’s disease and effects of coen-
zyme Q10. Ann. Neurol. 41, 160–165.
Kuwert, T., Lange, H.W., Boecker, H., Titz, H., Herzog, H., Aulich, A.,
Wang, B.C., Nayak, U., and Feinendegen, L.E. (1993). Striatal glucose
consumption in chorea-free subjects at risk of Huntington’s disease.
J. Neurol. 241, 31–36.
Leone, T.C., Lehman, J.J., Finck, B.N., Schaeffer, P.J., Wende, A.R.,
Boudina, S., Courtois, M., Wozniak, D.F., Sambandam, N., Bernal-
Mizrachi, C., et al. (2005). PGC-1alpha deficiency causes multi-system
energy metabolic derangements: muscle dysfunction, abnormal
weight control and hepatic steatosis. PLoS Biol. 3, e101.
Lin, J., Wu, P., Tarr, P., St-Pierre, J., Zhang, J., Mootha, V.K., Jager, S.,
Vianna, C., Reznick, R., Manieri, M., et al. (2004). Defects in adaptive
energy metabolism with hyperactivity in PGC-1alpha mutant mice.
Cell 119, 121–135.
Mantamadiotis, T., Lemberger, T., Bleckmann, S.C., Kern, H., Kretz,
O., Martin Villalba, A., Tronche, F., Kellendonk, C., Gau, D., Kapfham-
mer, J., et al. (2002). Disruption of CREB function in brain leads to
neurodegeneration. Nat. Genet. 31, 47–54.
Menalled, L.B., Sison, J.D., Dragatsis, I., Zeitlin, S., and Chesselet,
M.F. (2003). Time course of early motor and neuropathological anom-
alies in a knock-in mouse model of Huntington’s disease with 140 CAG
repeats. J Comp Neurol. 465, 11–26.
Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R.,
Strittmatter, W.J., and Greenamyre, J.T. (2002). Early mitochondrialcalcium defects in Huntington’s disease are a direct effect of polyglu-
tamines. Nat. Neurosci. 5, 731–736.
Puigserver, P., and Spiegelman, B.M. (2003). Peroxisome proliferator-
activated receptor-gamma coactivator 1 alpha (PGC-1 alpha):
transcriptional coactivator and metabolic regulator. Endocr. Rev. 24,
78–90.
Saluja, D., Vassallo, M.F., and Tanese, N. (1998). Distinct subdomains
of human TAFII130 are required for interactions with glutamine-rich
transcriptional activators. Mol. Cell. Biol. 18, 5734–5743.
Sandoval, J., Rodriguez, J.L., Tur, G., Serviddio, G., Pereda, J., Bou-
kaba, A., Sastre, J., Torres, L., Franco, L., and Lopez-Rodas, G.
(2004). RNAPol-ChIP: a novel application of chromatin immunoprecip-
itation to the analysis of real-time gene transcription. Nucleic Acids
Res. 32, 1–8.
Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998).
Huntingtin acts in the nucleus to induce apoptosis but death does
not correlate with the formation of intranuclear inclusions. Cell 95,
55–66.
Shimohata, T., Nakajima, T., Yamada, M., Uchida, C., Onodera, O.,
Naruse, S., Kimura, T., Koide, R., Nozaki, K., Sano, Y., et al. (2000).
Expanded polyglutamine stretches interact with TAFII130, interfering
with CREB-dependent transcription. Nat. Genet. 26, 29–36.
Sena-Esteves, M., Tebbets, J.C., Steffens, S., Crombleholme, T., and
Flake, A.W. (2004). Optimized large-scale production of high titer
lentivirus vector pseudotypes. J. Virol. Methods 122, 131–139.
Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L.,
Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S.,
and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowl-
edge-based approach for interpreting genome-wide expression
profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550.
Sugars, K.L., and Rubinsztein, D.C. (2003). Transcriptional abnormal-
ities in Huntington disease. Trends Genet. 19, 233–238.
Szebenyi, G., Morfini, G.A., Babcock, A., Gould, M., Selkoe, K., Sten-
oien, D.L., Young, M., Faber, P.W., MacDonald, M.E., McPhaul, M.J.,
and Brady, S.T. (2003). Neuropathogenic forms of huntingtin and
androgen receptor inhibit fast axonal transport. Neuron 40, 41–52.
Takahashi, Y., Rayman, J.B., and Dynlacht, B.D. (2000). Analysis of
promoter binding by the E2F and pRB families in vivo: distinct E2F
proteins mediate activation and repression. Genes Dev. 14, 804–816.
Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp,
A.H., Persichetti, F., Cattaneo, E., and MacDonald, M.E. (2000). Dom-
inant phenotypes produced by the HD mutation in STHdh(Q111)
striatal cells. Hum. Mol. Genet. 9, 2799–2809.
Vonsattel, J.P., and DiFiglia, M. (1998). Huntington disease. J. Neuro-
pathol. Exp. Neurol. 57, 369–384.
Wheeler, V.C., White, J.K., Gutekunst, C.A., Vrbanac, V., Weaver, M.,
Li, X.J., Li, S.H., Yi, H., Vonsattel, J.P., Gusella, J.F., et al. (2000). Long
glutamine tracts cause nuclear localization of a novel form of huntingtin
in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in
mice. Hum. Mol. Genet. 9, 503–513.
Zhai, W., Jeong, H., Cui, L., Krainc, D., and Tjian, R. (2005). In vitro
analysis of huntingtin-mediated transcriptional repression reveals mul-
tiple transcription factor targets. Cell 123, 1241–1253.
Zoghbi, H.Y., and Orr, H.T. (2000). Glutamine repeats and neurode-
generation. Annu. Rev. Neurosci. 23, 217–247.
Zucker, B., Luthi-Carter, R., Kama, J.A., Dunah, A.W., Stern, E.A., Fox,
J.H., Standaert, D.G., Young, A.B., and Augood, S.J. (2005). Tran-
scriptional dysregulation in striatal projection- and interneurons in
a mouse model of Huntington’s disease: neuronal selectivity and
potential neuroprotective role of HAP1. Hum. Mol. Genet. 14, 179–189.Cell 127, 59–69, October 6, 2006 ª2006 Elsevier Inc. 69
